Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of February 2020. The report details a strategic amendment to a Master Clinical Trial Collaboration Agreement with Bristol-Myers Squibb Company (BMS) regarding the development of Compugen's investigational anti-PVRIG antibody, COM701.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a contractual amendment and clinical trial strategy.
Material Changes
- Amendment to Collaboration Agreement: On February 14, 2020, Compugen and BMS amended their October 2018 agreement to alter the scope of clinical trials for COM701.
- Shift to Triple Combination Study: The parties agreed to initiate a triple combination study evaluating COM701, BMS's Opdivo (nivolumab), and BMS's anti-TIGIT antibody (BMS-986207). This replaces the previously planned expansion of a dual combination study (COM701 and Opdivo).
- Sponsorship Responsibility: Compugen will now sponsor a two-part Phase 1/2 trial for the triple combination in patients with advanced solid tumors, whereas the previous plan involved BMS sponsoring the expansion.
- Cost Structure: BMS will provide Opdivo and BMS-986207 at no cost to Compugen for this trial.
- Licensing Rights: Compugen retains global commercial rights to COM701. However, if Compugen seeks to license the compound in any territory during the "Exclusivity Period" (end of the Triple Combination study plus six months), it must first negotiate an exclusive license with BMS for three months. If no agreement is reached, Compugen is free to license to other parties.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, earnings outlook, or general risk factors. The primary operational focus is the execution of the new triple combination trial. The amendment introduces a specific contingency regarding commercial licensing: Compugen's ability to license COM701 to third parties during the Exclusivity Period is contingent upon the outcome of a mandatory three-month negotiation period with BMS.
Investor Verification Checklist
- Verify the specific terms of the "Exclusivity Period" and "Negotiation Period" in the amended agreement to understand potential delays in third-party licensing.
- Confirm the timeline for the initiation of the new Phase 1/2 triple combination trial.
- Review the full text of the press release (Exhibit 99.1) for additional details on the strategic rationale for shifting from a dual to a triple combination study.
- Monitor future filings for updates on the safety and tolerability data from the new trial design.